Genzyme received marketing approval from the FDA for Lumizyme (alglucosidase alfa), produced at the 4000 L bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the U.S. to treat patients with late-onset Pompe disease. Lumizyme is a lysosomal glycogen-specific enzyme for patients eight years and older with late (non-infantile) onset Pompe disease who do not have evidence of cardiac hypertrophy. “This is an important day for the Pompe com...